Recent News & Research

OncLive
Dr. Brahmer on the Utility of Consolidative Immunotherapy Vs Targeted Therapy in NSCLC ResearchTreatments

Dr. Brahmer on the Utility of Consolidative Immunotherapy Vs Targeted Therapy in NSCLC

*November 2021* Julie Renee Brahmer, MD, MSc, professor of oncology, co-director, Upper Aerodigestive Department, Bloomberg~Kimmel Institute for Cancer Immunotherapy, co-director, Cancer Immunology Program, director, Thoracic Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses questions regarding the role of consolidative immunotherapy vs targeted therapy in locally advanced non–small cell…
laurabbook@gmail.com
December 8, 2021
Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes ResearchTreatments

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

*November 2021* The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA non-small cell lung cancer (NSCLC). However, not all patients experienced favorable clinical outcomes with tyrosine kinase inhibitors (TKI), raising the necessity for further biomarker assessment. In this work, by…
laurabbook@gmail.com
December 8, 2021
OncLive
Overcoming Mechanisms of Resistance Remains at the Forefront for EGFR-Mutant NSCLC ResearchTreatments

Overcoming Mechanisms of Resistance Remains at the Forefront for EGFR-Mutant NSCLC

*November 2021* Although next-generation TKIs, such as osimertinib (Tagrisso), have helped to overcome resistance in EGFR-mutated non–small cell lung cancer (NSCLC), a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs, as well, according to Roy S. Herbst, MD,…
laurabbook@gmail.com
December 8, 2021
ESMO Open Cancer Horizons
Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies ResearchTreatments

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies

*October 2021* Highlights Acquired resistance mechanisms to osimertinib can be EGFR dependent or independent. First- and fourth-generation EGFR-TKIs are able to overcome EGFR-dependent resistance. MET and MEK inhibitors may overcome EGFR-independent resistance. Anti-HER/MET novel monoclonal antibody seems effective across multiple resistance mechanisms. Carboplatin/paclitaxel ± bevacizumab/atezolizumab represents a feasible option in…
laurabbook@gmail.com
December 8, 2021
CancerConnect
A Primer on EGFR TKIs and Their Resistance Mechanisms and Treatments ResearchTreatments

A Primer on EGFR TKIs and Their Resistance Mechanisms and Treatments

*November 2021* Note: The article below, In Depth Overview of Tyrosine Kinase Inhibitor Treatment of EGFR+ Lung Cancer, is taken from CancerConnect and lists and explains the different generations of TKIs, their modes of action and  resistance mechanisms that develop as well as their treatments. EGFR-targeted drugs that have been shown to benefit…
laurabbook@gmail.com
December 7, 2021
American Lung Association logo
What Can you Expect from a Lung Cancer Clinical Trial AdvocacyResearchTreatments

What Can you Expect from a Lung Cancer Clinical Trial

*November 2021* In this webinar, Dr. Mark A. Socinski, Executive Medical Director, Advent Health Cancer Institute, Orlando, FL, will explain the process of participating in a lung cancer clinical trial from beginning to end. Dr. Socinski will explain how typical lung cancer clinical trials are structured, how patients are monitored…
laurabbook@gmail.com
December 7, 2021
EGFR Resisters logo
EGFR Resisters and LCRF Research Partnership: First Study Grant Awarded! FundingResearchTreatments

EGFR Resisters and LCRF Research Partnership: First Study Grant Awarded!

*December 2021* Our first $150,000 LCRF grant awarded to Yang Tian, PhD from the Icahn School of Medicine at Mount Sinai. Her project is titled, “Targeting lung lineage plasticity to suppress Osimertinib-induced drug-tolerant persisters. Please view the announcement of this lung cancer study video here.
laurabbook@gmail.com
December 7, 2021
NIH Library of Medicine
Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation ResearchTreatments

Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation

*October 2021* Purpose: This study aimed to explore the clinical value of SBRT for primary lung lesions of EGFR-mutant NSCLC patients with non-oligometastatic disease during first-line EGFR-TKI treatment. Methods: We identified patients with stage IV EGFR-mutant non-oligometastatic NSCLC who were suitable to receive SBRT for the primary tumors after EGFR-TKI treatment. All…
laurabbook@gmail.com
November 12, 2021